- Home
- VINP vs RIGL Comparison
VINP vs RIGL Comparison
Compare VINP & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VINP | RIGL |
|---|---|---|
| Founded | 2009 | 1996 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 638.8M | 564.7M |
| IPO Year | 2020 | 2000 |
Fundamental Metrics
Financial Performance| Metric | VINP | RIGL |
|---|---|---|
| Price | $9.68 | $48.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $14.00 | ★ $45.67 |
| AVG Volume (30 Days) | 40.2K | ★ 255.7K |
| Earning Date | 05-11-2026 | 05-05-2026 |
| Dividend Yield | ★ 5.72% | N/A |
| EPS Growth | N/A | ★ 1867.68 |
| EPS | N/A | ★ 1.32 |
| Revenue | N/A | ★ $294,282,000.00 |
| Revenue This Year | $18.07 | N/A |
| Revenue Next Year | $12.74 | $12.75 |
| P/E Ratio | ★ $24.41 | $36.71 |
| Revenue Growth | N/A | ★ 64.15 |
| 52 Week Low | $9.19 | $24.84 |
| 52 Week High | $13.61 | $52.24 |
Technical Indicators
Market Signals| Indicator | VINP | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 54.38 | 66.57 |
| Support Level | $9.76 | $40.05 |
| Resistance Level | $10.26 | $49.10 |
| Average True Range (ATR) | 0.27 | 1.83 |
| MACD | 0.05 | 0.22 |
| Stochastic Oscillator | 77.16 | 83.12 |
Price Performance
Historical ComparisonAbout VINP Vinci Partners Investments Ltd.
Vinci Compass Investments Ltd is an alternative investment platform in Brazil offering asset management, wealth management, and financial advisory services. The company comprises of six business lines i) Global IP&S, (ii) Credit (including public & private credit, opportunistic capital solutions, and agribusiness credit), (iii) Private Equity, (iv) Equities, (v) Real Assets (including real estate, infrastructure and forestry) and (vi) Corporate Advisory.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.